45 episodes

The Stock2Me Podcast is your source for the latest news and updates on market trends and movers in high-profile industry sectors. We'll keep you in the loop regarding the companies on our watchlist and provide in-depth information about the inner workings and eccentricities of the ever-evolving North American markets.

The Stock2Me Podcast stock2me

    • News
    • 5.0 • 1 Rating

The Stock2Me Podcast is your source for the latest news and updates on market trends and movers in high-profile industry sectors. We'll keep you in the loop regarding the companies on our watchlist and provide in-depth information about the inner workings and eccentricities of the ever-evolving North American markets.

    • video
    Stock2Me Podcast featuring Two-Time Olympic Gold Medalist Abby Wambach on Behalf of Odyssey Health Inc. (ODYY) [Video Edition]

    Stock2Me Podcast featuring Two-Time Olympic Gold Medalist Abby Wambach on Behalf of Odyssey Health Inc. (ODYY) [Video Edition]

    Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy.
    Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health.
    “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

    • 19 min
    Stock2Me Podcast featuring Two-Time Olympic Gold Medalist Abby Wambach on Behalf of Odyssey Health Inc. (ODYY)

    Stock2Me Podcast featuring Two-Time Olympic Gold Medalist Abby Wambach on Behalf of Odyssey Health Inc. (ODYY)

    Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy.
    Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health.
    “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

    • 19 min
    Stock2Me Podcast featuring Return of FuelPositive Corp. (NHHHF) CEO Ian Clifford

    Stock2Me Podcast featuring Return of FuelPositive Corp. (NHHHF) CEO Ian Clifford

    Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. 
    Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. 
    “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

    • 18 min
    • video
    Stock2Me Podcast featuring Return of FuelPositive Corp. (NHHHF) CEO Ian Clifford [Video Edition]

    Stock2Me Podcast featuring Return of FuelPositive Corp. (NHHHF) CEO Ian Clifford [Video Edition]

    Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. 
    Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. 
    “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

    • 18 min
    Stock2Me Podcast featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka

    Stock2Me Podcast featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka

    Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms.
    To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology.
    “[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

    • 18 min
    • video
    Stock2Me Podcast featuring Lexaria Bioscience Corp. (LEXX) Chairman & CEO Chris Bunka [Video Edition]

    Stock2Me Podcast featuring Lexaria Bioscience Corp. (LEXX) Chairman & CEO Chris Bunka [Video Edition]

    Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms.
    To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology.
    “[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

    • 18 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In News

The New York Times
Rachel Maddow, MSNBC
NPR
The Daily Wire
MSW Media
Crooked Media